Senseonics (NYSEAMERICAN:SENS) Shares Gap Up to $3.62

Senseonics Holdings, Inc. (NYSEAMERICAN:SENS)’s share price gapped up prior to trading on Friday . The stock had previously closed at $3.62, but opened at $3.93. Senseonics shares last traded at $3.75, with a volume of 834,699 shares.

A number of equities analysts have recently commented on the company. Zacks Investment Research upgraded Senseonics from a “sell” rating to a “hold” rating in a report on Wednesday, March 10th. Stifel Nicolaus lifted their target price on Senseonics from $1.00 to $2.50 and gave the stock a “buy” rating in a report on Friday, March 5th. They noted that the move was a valuation call. SVB Leerink cut Senseonics from an “outperform” rating to a “market perform” rating and set a $3.00 target price for the company. in a report on Thursday, April 1st. Finally, Raymond James restated an “underperform” rating on shares of Senseonics in a report on Thursday, March 11th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $1.75.

The company has a market capitalization of $1.66 billion, a PE ratio of -3.17 and a beta of 0.41. The company has a 50-day simple moving average of $0.48.

Senseonics (NYSEAMERICAN:SENS) last announced its earnings results on Thursday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.63). Analysts expect that Senseonics Holdings, Inc. will post -0.11 earnings per share for the current year.

In other Senseonics news, Director Douglas A. Roeder sold 4,892,388 shares of the business’s stock in a transaction dated Friday, April 9th. The stock was sold at an average price of $2.39, for a total transaction of $11,692,807.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Douglas S. Prince sold 136,539 shares of the business’s stock in a transaction dated Tuesday, May 25th. The shares were sold at an average price of $1.90, for a total value of $259,424.10. Following the sale, the director now owns 231,795 shares in the company, valued at approximately $440,410.50. The disclosure for this sale can be found here. Insiders have sold a total of 10,276,039 shares of company stock worth $23,115,103 over the last ninety days. 5.60% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of SENS. Delphi Management Partners VIII L.L.C. purchased a new stake in shares of Senseonics in the fourth quarter worth about $8,585,000. Masters Capital Management LLC boosted its position in Senseonics by 369.0% during the first quarter. Masters Capital Management LLC now owns 9,380,649 shares of the company’s stock worth $24,765,000 after purchasing an additional 7,380,649 shares in the last quarter. BlackRock Inc. boosted its position in Senseonics by 101.1% during the first quarter. BlackRock Inc. now owns 5,637,619 shares of the company’s stock worth $14,883,000 after purchasing an additional 2,834,433 shares in the last quarter. Parian Global Management LP purchased a new position in Senseonics during the fourth quarter worth approximately $1,744,000. Finally, Morgan Stanley boosted its position in Senseonics by 319.4% during the first quarter. Morgan Stanley now owns 1,616,750 shares of the company’s stock worth $4,269,000 after purchasing an additional 1,231,301 shares in the last quarter. Hedge funds and other institutional investors own 16.01% of the company’s stock.

About Senseonics (NYSEAMERICAN:SENS)

Senseonics Holdings, Inc, a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days.

Read More: What is the balance sheet?

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.